Last 30 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -17.61 | — | — | — | — | 26.38 | 36.66 | — | — | 14.34 | 39.36 | — | 15.34 |
| — | — | — | — | — | +83.9% | -6.9% | — | — | +237.2% | +714.8% | — | +412.3% | |
| P/S Ratio | 7.29 | 6.49 | 3.88 | 24.66 | 29.93 | 5.75 | 5.83 | 37.11 | 29.57 | 4.30 | 7.27 | 38.58 | 5.97 |
| — | +12.8% | -33.5% | -33.5% | +1.2% | +33.8% | -19.8% | -3.8% | +395.0% | +99.0% | +191.9% | +1176.2% | +243.9% | |
| P/B Ratio | 1.00 | 1.21 | 1.28 | 1.39 | 1.16 | 1.41 | 1.52 | 1.00 | 1.11 | 1.26 | 1.31 | 1.30 | 1.39 |
| — | -13.9% | -16.0% | +38.8% | +4.1% | +12.3% | +15.9% | -23.0% | -19.8% | -31.8% | -30.2% | -43.4% | -50.2% | |
| P/FCF | 74.44 | 24.55 | 7.27 | 9.19 | — | — | — | 2.97 | — | 5.56 | 9.86 | 1.59 | — |
| — | — | — | +209.2% | — | — | — | +87.3% | — | -58.8% | +437.2% | -36.9% | — | |
| EV / EBITDA | — | — | 44.43 | — | — | 14.23 | 89.56 | — | — | 5.78 | 27.86 | — | 6.40 |
| — | — | -50.4% | — | — | +146.1% | +221.5% | — | — | +229.6% | +1164.1% | — | +219.2% | |
| EV / EBIT | — | — | 136.85 | — | — | 14.94 | 29.49 | — | — | 9.28 | 13.89 | — | 5.96 |
| — | — | +364.0% | — | — | +61.0% | +112.3% | — | — | +405.8% | +537.5% | — | +212.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
BioNTech SE's operating margin was -25.7% in Q4 2025, down 22.6 pp QoQ and down 38.1 pp YoY. The trailing four-quarter average of -128.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 20.5% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.6% | 63.3% | 90.2% | 70.7% | 54.2% | 79.5% | 85.6% | 53.5% | 68.5% | 87.9% | 81.9% | 2.9% | 92.5% |
| — | -20.5% | +5.4% | +32.1% | -20.9% | -9.5% | +4.5% | +1770.4% | -25.9% | -8.2% | +4.7% | -96.2% | +16.0% | |
| Operating Margin | -22.6% | -25.7% | -3.1% | -192.1% | -292.2% | 12.5% | 0.8% | -750.7% | -270.4% | 35.6% | 8.2% | -335.9% | 51.2% |
| — | -305.5% | -466.1% | +74.4% | -8.1% | -64.9% | -89.7% | -123.5% | -627.6% | -53.8% | -88.2% | -585.9% | -31.3% | |
| Net Margin | -39.6% | -33.6% | -1.9% | -148.2% | -227.5% | 21.8% | 15.9% | -627.7% | -168.0% | 31.0% | 17.9% | -113.5% | 39.3% |
| — | -254.1% | -111.9% | +76.4% | -35.4% | -29.6% | -11.3% | -452.8% | -527.1% | -41.9% | -65.2% | -317.1% | -32.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.7% | -1.6% | -0.2% | -2.1% | -2.2% | 1.3% | 1.0% | -4.1% | -1.6% | 2.3% | 0.8% | -0.9% | 2.4% |
| — | -219.0% | -115.0% | +50.1% | -38.4% | -41.0% | +28.5% | -355.6% | -165.6% | -80.8% | -92.0% | -108.9% | -91.0% | |
| ROA | -4.9% | -1.4% | -0.1% | -1.8% | -1.9% | 1.2% | 0.9% | -3.6% | -1.4% | 2.0% | 0.7% | -0.8% | 2.1% |
| — | -220.8% | -115.1% | +50.3% | -36.6% | -43.0% | +22.8% | -340.7% | -165.5% | -79.6% | -91.1% | -110.2% | -89.6% | |
| ROIC | -4.3% | -1.7% | -0.4% | -4.3% | -4.2% | 1.1% | 0.1% | -7.2% | -3.8% | 5.1% | 0.9% | -5.6% | 6.4% |
| — | -249.1% | -587.1% | +40.3% | -11.4% | -77.9% | -90.4% | -27.5% | -159.8% | -87.9% | -96.8% | -130.0% | -81.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +6.2% | +4.2% | +9.1% | +30.8% | +21.0% | +25.4% | +29.2% | +14.3% | +2.3% | -31.9% | -27.2% | -11.4% | |
| Debt / EBITDA | — | — | 3.17 | — | — | 0.81 | 4.44 | — | — | 0.36 | 1.76 | — | 0.33 |
| — | — | -28.5% | — | — | +123.5% | +151.5% | — | — | +466.9% | +1459.4% | — | +754.2% | |
| Current Ratio | 7.54 | 7.54 | 7.12 | 8.61 | 10.18 | 7.45 | 7.33 | 7.54 | 11.38 | 9.43 | 10.37 | 10.56 | 12.95 |
| — | +1.1% | -2.8% | +14.2% | -10.5% | -21.0% | -29.4% | -28.7% | -12.1% | +26.9% | +93.1% | +105.1% | +156.4% | |
| Quick Ratio | 7.49 | 7.49 | 7.02 | 8.48 | 10.02 | 7.34 | 7.21 | 7.40 | 11.16 | 9.26 | 10.14 | 10.32 | 12.68 |
| — | +2.0% | -2.6% | +14.7% | -10.3% | -20.7% | -28.9% | -28.3% | -11.9% | +27.2% | +91.4% | +104.0% | +157.1% | |
| Interest Coverage | -45.74 | -35.82 | 62.89 | -121.29 | -66.13 | — | 31.98 | -109.58 | -68.91 | 19.88 | 111.18 | -316.75 | 622.24 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 30 years · Updated daily
Deep dive into BNTX consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BNTX stock.
BioNTech SE's current P/E is -17.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioNTech SE's current operating margin is -22.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioNTech SE's business trajectory between earnings reports.